Polio Outbreak in Pakistan
Pakistan continues to be dealing with a polio outbreak as four fresh cases have emerged, pushing the national tally to 37 this year, according to health officials on October 19, 2024. Health officials said that the regional reference laboratory for polio eradication at the National Institute of Health in Islamabad confirmed wild poliovirus type-1 (WPV1) in two children-one from each Balochistan and Khyber-Pakhtunkhwa.
In recent cases, a girl has been affected from Pishin, and two boys from Chaman and Noshki of Balochistan, and a girl from Lakki Marwat in KP. These are the first detections of the virus within Noshki and Lakki Marwat this year; isolated cases of poliovirus were previously reported within Chaman and Pishin. The province of Balochistan was the worst hit with 20 cases, Sindh had 10, Khyber Pakhtunkhwa had five, and Punjab and Islamabad had one case each.
A gigantic fight against polio has been on going in Pakistan- especially in Balochistan and southern KP-over the last two years. Immunisation campaigns have often been suspended or delayed because of local protests, insecurity, and community boycotts. Consequently, quite a number of children did not get the necessary vaccinations, making existing patches of vulnerability for the virus to flow within those pockets.
Noshki, located near Afghanistan's border, and Lakki Marwat have also recently reported some positive environmental samples that confirm the virus is present here, said a local reference laboratory official. Samples of latest cases are currently under genetic sequencing for checking spread of virus and origin.
As the threat of polio continues to grow, Pakistan has vowed to mount a nationwide campaign against it beginning from October 28. With the zeal to tackle the menace in the most effective manner, over 45 million children under the age of five will be vaccinated across the country.
Today, Afghanistan and Pakistan remain one of the few countries where polio has not yet been eradicated. The WHO said the virus remains a potential serious public health threat in areas with low vaccination coverage and weak surveillance.
The country declared itself polio-free since 2014 and has kept the disease on bay almost a decade with very robust vaccination programs; however, two cases of vaccine-derived poliovirus cases reported in recent days from Meghalaya create some amount of doubts over a possible resurgence. Experts observe that in India, despite these detections taking place, strong coverage of vaccination at 90-95% and mandatory surveillance measures keep the risk of this widespread outbreak at bay.
The experts point out, however, that such stable situation in India requires continued surveillance. "Countries like Pakistan and parts of Africa remain at a high risk because vaccination rates in those areas are much lower," Dr. Siddharth, public health expert, said. Vaccination is an indispensable act in order to avoid the spread of this incapacitating disease that manifests most importantly as a nervous system affliction leading to the paralysis of a long period.
With concerted efforts from health authorities, there is hope someday that the scourge of polio will be completely eradicated from the face of the earth and future generations will never suffer from its effects.
Credit: AI Image
The US has lost its measles elimination status after 26 years, with Bolivia and Mexico also losing the designation, the Pan American Health Organization (PAHO) announced on Tuesday. The decision follows more than 12 months of continuous measles transmission in the US.
Amid the resurgence, a CDC-led report has identified 112 measles infections among pregnant women in the US between January 2025 and September 2026, along with 13 cases of congenital measles in newborns. Nearly all the women were unvaccinated or had an unknown vaccination status.
The actual number of infections among pregnant women may be higher. A separate CIDRAP News investigation based on state health department data identified at least 167 pregnant women infected in 2025 and 2026.
Also Read: What Happens After Measles Infection? The Hidden Risks That Can Last For Years
The CDC-led report, published in NEJM Evidence journal, found that 108 (96%) of the 112 cases occurred during outbreaks involving 50 or more cases.
Of the infected women, 110 (98%) had received no MMR vaccine doses or had an unknown vaccination status.
Twenty-six women (23%) were hospitalized for reasons unrelated to childbirth, while 11 (10%) developed pneumonia.
“Even though measles is an old disease, measles in pregnancy is an emerging area that we need to learn about,” said Michelle Barton, a professor at the Schulich School of Medicine & Dentistry at Western University.
Read More: Congenital Measles Reported In Pennsylvania For First Time In Decades: What Parents Should Know
The report recorded 21 pregnancy outcomes within 14 days of maternal rash onset: 19 live births and two pregnancy losses, including one miscarriage and one stillbirth.
Eight babies were born prematurely, and eight required admission to a neonatal intensive care unit (NICU).
The report noted that 13 babies had congenital measles and tested positive for the virus. Of these, six developed symptoms, including one with signs compatible with meningoencephalitis, a potentially life-threatening inflammation of the brain and surrounding membranes.
The authors said the outbreaks highlighted measles' risks to maternal and newborn health.
Many doctors and nurses treating these patients have never encountered measles, relying largely on medical training and professional guidelines to manage the infections.
The CDC recommends intravenous immunoglobulin as post-exposure prophylaxis for pregnant women without documented MMR vaccination or other evidence of immunity who are exposed to measles.
Newborns exposed to measles in the womb should also receive immunoglobulin at birth. Congenital measles can cause severe neurological complications, including subacute sclerosing panencephalitis (SSPE), a rare, progressive brain disorder.
The US is experiencing its highest measles burden in more than three decades. Since 2025, approximately 7,700 people have been infected and 13 have died, according to the figures cited in the report.
As of November 12, the CDC had confirmed 5,412 cases and six deaths in 2026. States had reported 10 deaths.
The rise in infections has coincided with declining vaccination rates and growing vaccine hesitancy. US Health Secretary Robert F. Kennedy Jr. has repeatedly questioned measles vaccine safety without scientific evidence supporting those claims.
The CDC said it would work to stop outbreaks and regain elimination status by supporting states and providing sustained national leadership.
"The measles elimination designation is not what protects Americans; vaccination does," CDC Director Erica Schwartz said.
Credit: AI Image
A new trial by Novo Nordisk found that Wegovy (semaglutide) reduced body mass index (BMI) by at least 10% in nearly 80% of children with obesity aged 6 to under 12 years.
The phase 3 STEP Young trial found that 78.7% of children receiving semaglutide achieved this reduction after 68 weeks, compared with none in the placebo group.
However, the findings raise questions about the safety of GLP-1 medications in younger children. The World Health Organization (WHO) does not recommend weight-loss medicines for treating obesity in children under 10, citing limited evidence on their long-term safety and effectiveness.
Also read: Wegovy & Zepbound Are Not Approved By US FDA For Children Under 12: So Why Are Prescriptions Rising?
The phase 3 trial evaluated once-weekly semaglutide injections in children aged 6 to under 12 with obesity. Participants also followed a reduced-calorie diet and increased their physical activity.
The findings were presented at ObesityWeek 2026 and published in The New England Journal of Medicine.
After 68 weeks:
Childhood obesity increases the risk of type 2 diabetes, high blood pressure, abnormal cholesterol levels and obstructive sleep apnea. Severe obesity can also affect a child's physical health, emotional well-being and daily life, with complications that may persist into adulthood.
The trial also found improvements in multiple cardiometabolic measures among children receiving semaglutide.
"Encouragingly, treating obesity with semaglutide was accompanied by improvements in multiple cardiometabolic measures, suggesting that effective treatments for severe childhood obesity may shift a child's trajectory back towards one of improving weight-related health," said Ania M. Jastreboff, Professor of Medicine and Pediatrics at Yale School of Medicine and Director of the Yale Obesity Research Center.
What Are The Side Effects?
Read More: Are GLP-1 Drugs Safe for Children? Study Finds Nutritional Deficiency in Nearly 17% Within a Year
Adverse events were reported in 96% of children receiving semaglutide and 93% receiving placebo. Gastrointestinal problems were the most common and occurred more frequently among children taking the drug.
Common gastrointestinal side effects associated with semaglutide include nausea, vomiting, diarrhoea, constipation and abdominal pain.
Other potential risks associated with GLP-1 treatment include gallbladder problems, pancreatitis and dehydration.
The WHO does not recommend weight-loss medicines, bariatric surgery or weight-management devices for children aged 0 to 9, as there is insufficient evidence on GLP-1 drugs in younger populations.
Instead, it recommends healthy eating, physical activity and behavioural support for children and their caregivers.
For adolescents aged 10 to 19, approved obesity medicines may be considered alongside structured lifestyle interventions.
Read More: Childhood Obesity In India To Surge To 56 Million By 2040, Says Global Report
Despite these recommendations, GLP-1 prescriptions among younger children in the US are rising.
A NYU Langone Health study analysing health records of more than 3.5 million children found that prescriptions among those aged 8 to 11 with obesity increased more than 300-fold between 2019 and June 2026.
The GLP-1 medications approved for adolescents by the US FDA are not necessarily approved for children under 12.
However, a study from Northwestern University and Ann & Robert H. Lurie Children's Hospital of Chicago flagged nutritional deficiencies among young children taking GLP-drugs.
It showed that 16.8% of children aged 10 to 17 receiving GLP-1 medications developed a nutritional deficiency within a year. Vitamin D deficiency was the most common, affecting 12.4% of patients.
Amid limited long-term safety data, experts are concerned about prescribing appetite-suppressing drugs to children who are still growing, particularly because reduced appetite could lead to inadequate calorie and nutrient intake.
Credit: Health Ministry/X
Malaria cases and deaths in India declined by nearly 80% between 2015 and 2025, President Droupadi Murmu said on Tuesday, while warning that climate change, unplanned urbanization and growing mosquito resistance could create new challenges for malaria elimination.
Speaking at the inauguration of the Golden Jubilee celebrations of the Indian Council of Medical Research–National Institute of Malaria Research (ICMR–NIMR), the President called for sustained vigilance, stronger surveillance and greater community participation to achieve malaria elimination.
The President noted that malaria remains a serious public health challenge in several countries, including India.
Recalling the situation at the time of independence, she said the vector-borne disease was among the country's most critical public health challenges. She also shared her personal observations of how malaria affected people's lives.
"During the monsoon season, fever was often accepted as an inevitable hardship of life. Children were unable to attend school, while farmers and laborers were often left unable to work for days on end. For the people, malaria was not merely a health issue—it was deeply intertwined with their livelihoods, education, and future," she said.
India has since made significant progress through sustained public health interventions. Between 2015 and 2025, malaria cases and deaths declined by nearly 80%, while the number of high-burden districts fell from 155 to 33.
As many as 160 districts reported zero indigenous malaria cases between 2022 and 2025, reflecting progress in interrupting local transmission and implementing targeted malaria control and elimination measures.
Calling the progress "remarkable", the President credited improved healthcare services, modern diagnostic techniques, effective medicines, mosquito-control campaigns and community participation for curbing the disease.
Also read: El Niño Could Worsen Dengue, Malaria And Heat Illness: Why WHO Declared A Health Emergency
Despite the progress, malaria remains a challenge in certain regions, the President said, stressing the need for "sustained vigilance and effective efforts" to eliminate the disease.
She highlighted the importance of robust systems for malaria testing, treatment, surveillance and mosquito control.
Research aimed at developing new drugs and vaccines, along with public awareness and community participation, will also be vital for malaria elimination, she said.
The President warned that climate change, unplanned urbanization and growing mosquito resistance to insecticides could create new obstacles to malaria elimination efforts.
She also urged citizens to contribute to prevention efforts by avoiding water stagnation, eliminating mosquito breeding sites and maintaining a clean environment.
Beyond malaria, she noted that rising global temperatures and shifting monsoon patterns are further intensifying the challenge posed by dengue.
Addressing the gathering, Union Minister of Health and Family Welfare Jagat Prakash Nadda said India's progress in malaria control over the past decade was the result of a comprehensive approach involving research on mosquito behaviour and malaria parasites, community participation, effective prevention, early diagnosis and appropriate treatment.
Highlighting India's progress in malaria control, Nadda noted that the country, which accounts for approximately 16% of the global population, contributes around 0.7% of global malaria cases and 0.6% of malaria deaths.
The Union Minister also appreciated India's exit from the WHO's High Burden to High Impact initiative and expressed confidence in achieving malaria elimination by 2030.
"We will eliminate malaria by 2030 by bringing about the necessary changes in our strategies and policies," he said, calling upon ICMR–NIMR to work with renewed commitment.
The Minister also highlighted ICMR's contributions to medical innovation, including MedTech Mitra, Patent Mitra and ELISA-based molecular diagnostics for dengue, chikungunya, Japanese encephalitis and other infectious diseases.
© $2026 Times Horizon Private Limited